EVMN

Evommune, Inc.

9.65

USD

+0.28

+2.99%

Sep 18, 15:59 UTC -4

Closed

After-Market

9.65

0.00

+0.05%

Evommune, Inc. Profile

About

Evommune Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. Evommune Inc. is based in PALO ALTO, Calif.

Info & Links

CEO

Luis Pena

Headquarters

1841 Page Mill Road, Suite 100
Palo Alto, CA 94304, UNITED STATES

Auditor

BDO USA, P.C.

Share holders

113

Employees

Evommune, Inc. Statistics

Valuation Measures

Market Capitalization²

350.40M

Enterprise Value

290.80M

Enterprise Value/EBITDA(ttm)

-2.87

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

1.25

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-31.19%

Return on Equity(ttm)

-62.63%

Return on Invested Capital(ttm)

-25.63%

Return on Assets(ttm)

-40.55%

Income Statement

Revenue(ttm)

10.00M

Revenue Per Share(ttm)

0.28

Gross Profit(ttm)

10.00M

EBITDA(ttm)³

-101.23M

Net Income Available to Common(ttm)

-94.67M

Diluted EPS(ttm)

-11.03

Share Statistics

Beta (5Y Monthly)

52-Week Change

S&P 500 52-Week Change

17.10%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

36.29M

Dividend Yield

0.00%

Float⁴

25.00M

% Held by Insiders

31.10%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

200.79M

Total Cash Per Share(mrq)

5.53

Total Debt(mrq)

434.00K

Total Debt/Equity(mrq)

0.16%

Current Ratio(mrq)

11.68%

Quick Ratio(mrq)

11.68%

Book Value Per Share(mrq)

7.65

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.32

Free Cash Flow(ytd)

-48.09M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.